- Home
- NDRA vs RELI Comparison
NDRA vs RELI Comparison
Compare NDRA & RELI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDRA
- RELI
- Stock Information
- Founded
- NDRA 2007
- RELI 2013
- Country
- NDRA United States
- RELI United States
- Employees
- NDRA N/A
- RELI N/A
- Industry
- NDRA Biotechnology: Electromedical & Electrotherapeutic Apparatus
- RELI Specialty Insurers
- Sector
- NDRA Health Care
- RELI Finance
- Exchange
- NDRA Nasdaq
- RELI Nasdaq
- Market Cap
- NDRA 3.6M
- RELI 3.3M
- IPO Year
- NDRA 2017
- RELI N/A
- Fundamental
- Price
- NDRA $6.01
- RELI $2.14
- Analyst Decision
- NDRA Strong Buy
- RELI Strong Buy
- Analyst Count
- NDRA 1
- RELI 1
- Target Price
- NDRA $14,000.00
- RELI $119.00
- AVG Volume (30 Days)
- NDRA 36.2K
- RELI 5.6M
- Earning Date
- NDRA 11-15-2024
- RELI 11-07-2024
- Dividend Yield
- NDRA N/A
- RELI N/A
- EPS Growth
- NDRA N/A
- RELI N/A
- EPS
- NDRA N/A
- RELI N/A
- Revenue
- NDRA N/A
- RELI $14,078,473.00
- Revenue This Year
- NDRA N/A
- RELI N/A
- Revenue Next Year
- NDRA N/A
- RELI N/A
- P/E Ratio
- NDRA N/A
- RELI N/A
- Revenue Growth
- NDRA N/A
- RELI 4.71
- 52 Week Low
- NDRA $4.01
- RELI $1.18
- 52 Week High
- NDRA $2,240.00
- RELI $18.53
- Technical
- Relative Strength Index (RSI)
- NDRA 51.58
- RELI 49.98
- Support Level
- NDRA $5.60
- RELI $1.73
- Resistance Level
- NDRA $6.29
- RELI $2.50
- Average True Range (ATR)
- NDRA 0.60
- RELI 0.41
- MACD
- NDRA 0.02
- RELI -0.07
- Stochastic Oscillator
- NDRA 27.29
- RELI 27.33
About NDRA ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
About RELI Reliance Global Group Inc.
Reliance Global Group Inc operates as a holding company with diversified interests in the insurance market, as well as other related sectors. The company focuses on growing by pursuing an acquisition strategy, initially and primarily focused on wholesale and retail insurance agencies. Its primary strategy is to identify specific risks to reward arbitrage opportunities and develop these on a national platform, thereby increasing revenues and returns, and then identify and acquire undervalued wholesale and retail insurance agencies with operations in growing or underserved segments, expand and optimize their operations, and achieve asset value appreciation while generating interim cash flows. The company generates revenue in the form of commissions.